Evaluation of the humoral response in patients receiving half doses of AstraZeneca and BNT162b2 vaccines in a heterogenous prime-boost schedule.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210801052044N1

Enrollment

Registered

2021-08-29

Start date

2021-03-30

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The humoral response to the half-doses of AstraZeneca and BNT162b2 vaccines in a heterogenous prime-boost schedule.. Other serum reaction due to vaccination

Interventions

Intervention 1: . Intervention 2: Control group: Vaccination with BNT162b2 vaccine (Comirnaty,Pfizer/BioNTech), 2 full doses (0,3ml), dose interval 21 days. Blood draws for antibody testing: the day o

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Willingness to take part in the clinical trial Age between 18 and 55 years old

Exclusion criteria

Exclusion criteria: Age above 55 years old Diagnosed with diabetes, hypertension, heart disease, chronic pulmonarydiseases, severe allergies Obesity as defined by BMI > 30

Design outcomes

Primary

Measure	Time frame
Anti-SARS-CoV-2 antibody level. Timepoint: On the day of dose-2 of the vaccine and 8-10 days later. Method of measurement: IVD Elecsys Anti-SARS-CoV-2 S assay (Roche Diagnostics).	—

Countries

Poland

Contacts

Public ContactKrzysztof Lukaszuk

Invicta Research and Development Center

sekretariatlukaszuk@invicta.pl+48 58 585 88 10

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026